Cargando…

Prevalence of Established Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus in the UK

INTRODUCTION: The results of recently completed cardiovascular outcomes trials in patients with type 2 diabetes mellitus (T2DM) suggest that sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide (GLP) 1 receptor agonists have enhanced cardioprotective properties in patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lautsch, Dominik, Wang, Tongtong, Yang, Lingfeng, Rajpathak, Swapnil N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6848348/ https://www.ncbi.nlm.nih.gov/pubmed/31583647 http://dx.doi.org/10.1007/s13300-019-00698-9

Ejemplares similares

Individualized HbA(1c) Goals, and Patient Awareness and Attainment of Goals in Type 2 Diabetes Mellitus: A Real-World Multinational Survey
por: Lautsch, Dominik, et al.
Publicado: (2021)

Budget Impact of Oral Semaglutide Intensification versus Sitagliptin among US Patients with Type 2 Diabetes Mellitus Uncontrolled with Metformin
por: Wehler, Elizabeth, et al.
Publicado: (2020)

Secondary metformin monotherapy failure in individuals with type 2 diabetes mellitus
por: Weiss, Tracey, et al.
Publicado: (2021)

Medication use by US patients with pulmonary hypertension associated with chronic obstructive pulmonary disease: a retrospective study of administrative data
por: Weiss, Tracey J., et al.
Publicado: (2022)

Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK
por: Weiss, Tracey, et al.
Publicado: (2022)

Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States
por: Weiss, Tracey, et al.
Publicado: (2020)

Comparative Efficacy of Dual and Single Initiation of Add-On Oral Antihyperglycemic Agents in Type 2 Diabetes Uncontrolled on Metformin Alone: A Systematic Literature Review and Network Meta-Analysis
por: Lautsch, Dominik, et al.
Publicado: (2020)

Retrospective Cohort Analysis of the Reduced Burden of Hypoglycemia Associated with Dipeptidyl Peptidase-4 Inhibitor Use in Patients with Type 2 Diabetes Mellitus
por: Tang, Yuexin, et al.
Publicado: (2018)

Effect of dipeptidyl peptidase-4 inhibitors on postprandial glucagon level in patients with type 2 diabetes mellitus: A systemic review and meta-analysis
por: Chai, Shangyu, et al.
Publicado: (2022)

Novel pharmacological therapy in type 2 diabetes mellitus with established cardiovascular disease: Current evidence
por: Pozo, Leonardo, et al.
Publicado: (2019)

Sulfonylurea use and the risk of hospital readmission in patients with type 2 diabetes
por: Heaton, Pamela C., et al.
Publicado: (2016)

Metformin adherence and discontinuation among patients with type 2 diabetes: A retrospective cohort study
por: Tang, Yuexin, et al.
Publicado: (2020)

Impact of dipeptidyl peptidase-4 inhibitors on glucose-dependent insulinotropic polypeptide in type 2 diabetes mellitus: a systematic review and meta-analysis
por: Chai, Shangyu, et al.
Publicado: (2023)

Prevalence and incidence of microvascular and macrovascular complications over 15 years among patients with incident type 2 diabetes
por: An, Jaejin, et al.
Publicado: (2021)

Severity of hypoglycaemia and health‐related quality of life, work productivity and healthcare costs in patients with type 2 diabetes in Europe
por: Pawaskar, Manjiri, et al.
Publicado: (2018)

Statin Therapy and Risk of Developing Type 2 Diabetes: A Meta-Analysis
por: Rajpathak, Swapnil N., et al.
Publicado: (2009)

Causal Association of Type 2 Diabetes Mellitus and Glycemic Traits With Cardiovascular Diseases and Lipid Traits: A Mendelian Randomization Study
por: Huang, Mingkai, et al.
Publicado: (2022)

N‐terminal pro‐B‐type natriuretic peptide testing patterns in patients with heart failure with reduced ejection fraction
por: Januzzi, James L., et al.
Publicado: (2021)

The prevalence of cardiovascular disease in adults with type 2 diabetes mellitus in Saudi Arabia - CAPTURE study
por: Alguwaihes, Abdullah M., et al.
Publicado: (2023)

All-cause mortality and cardiovascular events in a Spanish nonagenarian cohort according to type 2 diabetes mellitus status and established cardiovascular disease
por: Salinero-Fort, MA, et al.
Publicado: (2022)

Effect of Medication Copayment on Adherence and Discontinuation in Medicare Beneficiaries with Type 2 Diabetes: A Retrospective Administrative Claims Database Analysis
por: Pawaskar, Manjiri D., et al.
Publicado: (2018)

Fat Mass is Associated with Subclinical Left Ventricular Systolic Dysfunction in Patients with Type 2 Diabetes Mellitus Without Established Cardiovascular Diseases
por: Liu, Jie, et al.
Publicado: (2023)

Dose distribution and up‐titration patterns of metformin monotherapy in patients with type 2 diabetes
por: Iglay, Kristy, et al.
Publicado: (2019)

Implementation of Empagliflozin in Patients with Diabetes Mellitus Type 2 and Established Cardiovascular Disease: Estimation of 5-Year Survival and Costs in Sweden
por: Bernfort, Lars, et al.
Publicado: (2020)

Prognostic Interplay Between COVID-19 and Heart Failure With Reduced Ejection Fraction
por: Greene, STEPHEN J., et al.
Publicado: (2022)

Cardiovascular Disease in Japanese Patients with Type 2 Diabetes Mellitus
por: Fujihara, Kazuya, et al.
Publicado: (2018)

Diabetes Mellitus Type 2 and Cardiovascular Diseases-Risk Assessment
por: Avdagic-Terzic, Mirsada, et al.
Publicado: (2022)

Efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus and established cardiovascular disease using insulin: A VERTIS CV substudy
por: Lingvay, Ildiko, et al.
Publicado: (2021)

Effects of conformance to type 2 diabetes guidelines on health care resource utilization, clinical outcomes, and cost: A retrospective claims analysis
por: Mehta, Rajesh R., et al.
Publicado: (2020)

Influence of dipeptidyl peptidase-4 inhibitors on glycemic variability in patients with type 2 diabetes: A meta-analysis of randomized controlled trials
por: Chai, Shangyu, et al.
Publicado: (2022)

Prevalence of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus in Iran: A Systematic Review and Meta-Analysis
por: Kazeminia, Mohsen, et al.
Publicado: (2020)

Use of the Estimated Glucose Disposal Rate as a Measure of Insulin Resistance in an Urban Multiethnic Population With Type 1 Diabetes
por: Epstein, Eric J., et al.
Publicado: (2013)

Association Between Switching to a High-Deductible Health Plan and Discontinuation of Type 2 Diabetes Treatment
por: Fendrick, A. Mark, et al.
Publicado: (2019)

Cardiovascular Disease in Type 1 Diabetes Mellitus: Epidemiology and Management of Cardiovascular Risk
por: Colom, Cristina, et al.
Publicado: (2021)

Type 2 Diabetes Mellitus and Cardiovascular Disease: Genetic and Epigenetic Links
por: De Rosa, Salvatore, et al.
Publicado: (2018)

Acetylcarnitine Is Associated With Cardiovascular Disease Risk in Type 2 Diabetes Mellitus
por: Zhao, Shuo, et al.
Publicado: (2021)

Development and validation of a model to predict cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease
por: Stevens, Susanna R., et al.
Publicado: (2022)

Diabetes Mellitus and Cardiovascular Disease
por: Aganovic, Izet
Publicado: (2003)

The Correlation between Type 2 Diabetes Mellitus and Cardiovascular Disease Risk Factors in the Elderly
por: Zhang, Lijuan, et al.
Publicado: (2022)

Prevalence of Microalbuminuria in Type 2 Diabetes Mellitus
por: Sana, Muhammad Ahsan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_el97a9938fk7p0a91n87f192eu